摘要
目的:分析薄芝糖肽临床应用情况,为临床合理用药提供参考。方法:检索中国期刊全文数据库(CNKI)、万方数据库、维普资讯网(VIP)收录的薄芝糖肽相关文献,对薄芝糖肽主要临床应用(同病种文献发表数量大于3篇)及不良反应进行统计和分析。结果:检索得文献163篇,包含临床应用文献137篇,其中文献发表数大于3篇的病种有尖锐湿疣(9篇)、带状疱疹(6篇)、手足口病(6篇)、寻常型银屑病(6篇)、肺癌(5篇)、小儿反复呼吸道感染(4篇)、乙型肝炎(9篇),共计45篇。45篇临床应用文献中有32篇(共1 772例)涉及不良反应病例,有49例发生不良反应,发生率为2.77%,以皮肤及其附件损害为主(10例,20.0%)。ADR病例报道11篇,涉及病例数20例,以寒战和发热为主(13例,37.2%)。结论:薄芝糖肽作为辅助用药在临床上主要与其他药物联合应用,能够增强主要治疗药物的疗效,不良反应发生率低且以皮肤及其附件损害为主。
Objective： To analyze the clinical application of Bozhi glycopeptides to provide reference for its rational use in clinics. Methods ： The related literatures of Bozhi glycopeptides from the databases of CNKI, Wanfang and VIP were retrieved. The main clinical application （ the number of literatures on the same disease entities was above 3） and ADR were analyzed and evaluated. Results： A total of 163 literatures were found, including 137 clinical application and 11 ADR case reports. The disease with the number of literatures a- bove 3 included condyloma acuminatum （9 literatures）, herpes zoster （6 literatures）, hand-foot-mouth disease （6 literatures）, psoriasis vulgaris （6 literatures）, lung cancer （5 literatures）, repeated respiratory infection （4 literatures） and hepatitis B （9 literatures）, and the total number was 45. Among them, 32 literatures （ 1 772 cases） involved ADR, and 49 cases （2.77%） of ADR were reported, and the main performance was skin and its appendages damage （ 10 cases, 20.0% ）. Totally 11 ADR case reports mainly involved rigors and fever （ 13 cases, 37.2% ）. Conclusion： Bozhi glycopeptides as an adjuvant drug is mainly combined with other drugs to enhance the effi- cacy of mian drugs in clinical application, which shows low incidence of ADR mainly including skin and its appendages damage.
出处
《中国药师》
CAS
2016年第6期1174-1179,共6页
China Pharmacist
关键词
薄芝糖肽
临床应用
药品不良反应
文献综述
Bozhi glycopeptides
Clinical application
Adverse drug reaction
Bibliometric analysis
